BRPI0912266A2 - derivado de óxido de benzotiofeno ou um sal do mesmo, composto, e, composição farmacêutica - Google Patents

derivado de óxido de benzotiofeno ou um sal do mesmo, composto, e, composição farmacêutica

Info

Publication number
BRPI0912266A2
BRPI0912266A2 BRPI0912266A BRPI0912266A BRPI0912266A2 BR PI0912266 A2 BRPI0912266 A2 BR PI0912266A2 BR PI0912266 A BRPI0912266 A BR PI0912266A BR PI0912266 A BRPI0912266 A BR PI0912266A BR PI0912266 A2 BRPI0912266 A2 BR PI0912266A2
Authority
BR
Brazil
Prior art keywords
salt
compound
pharmaceutical composition
oxide derivative
benzothiophene oxide
Prior art date
Application number
BRPI0912266A
Other languages
English (en)
Inventor
Hiroshi Kato
Tetsuro Nakamura
Original Assignee
Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyama Chemical Co Ltd filed Critical Toyama Chemical Co Ltd
Publication of BRPI0912266A2 publication Critical patent/BRPI0912266A2/pt
Publication of BRPI0912266B1 publication Critical patent/BRPI0912266B1/pt
Publication of BRPI0912266B8 publication Critical patent/BRPI0912266B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0912266A 2008-05-28 2009-05-26 composto derivado de óxido de benzotiofeno, e, composição farmacêutica BRPI0912266B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008-139007 2008-05-28
JP2008139007 2008-05-28
PCT/JP2009/059576 WO2009145171A1 (ja) 2008-05-28 2009-05-26 新規なベンゾチオフェンオキシド誘導体またはその塩

Publications (3)

Publication Number Publication Date
BRPI0912266A2 true BRPI0912266A2 (pt) 2015-10-13
BRPI0912266B1 BRPI0912266B1 (pt) 2019-07-09
BRPI0912266B8 BRPI0912266B8 (pt) 2021-05-25

Family

ID=41377044

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0912266A BRPI0912266B8 (pt) 2008-05-28 2009-05-26 composto derivado de óxido de benzotiofeno, e, composição farmacêutica

Country Status (20)

Country Link
US (1) US8026232B2 (pt)
EP (1) EP2287160B1 (pt)
JP (1) JP5552424B2 (pt)
KR (1) KR101615114B1 (pt)
CN (1) CN102046620B (pt)
AU (1) AU2009252368B2 (pt)
BR (1) BRPI0912266B8 (pt)
CA (1) CA2725307C (pt)
CY (1) CY1115355T1 (pt)
DK (1) DK2287160T3 (pt)
ES (1) ES2465005T3 (pt)
HR (1) HRP20140495T1 (pt)
IL (1) IL209443A (pt)
MX (1) MX2010012787A (pt)
NZ (1) NZ589448A (pt)
PL (1) PL2287160T3 (pt)
PT (1) PT2287160E (pt)
SI (1) SI2287160T1 (pt)
WO (1) WO2009145171A1 (pt)
ZA (1) ZA201008354B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2464358C (en) 2001-10-19 2011-05-24 Toyama Chemical Co., Ltd. Alkyl ether derivatives or their salts
ES2721666T3 (es) * 2012-02-22 2019-08-02 Fujifilm Toyama Chemical Co Ltd Composición farmacéutica sólida que contiene 1-(3-(2-(1-benzotiofen-5-il)etoxi)propil)azetidin-3-ol o una sal del mismo
WO2018124281A1 (ja) * 2016-12-28 2018-07-05 富山化学工業株式会社 外用組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002354579A1 (en) * 2001-07-12 2003-01-29 Pharmacia And Upjohn Company Amide-containing compound having improved solubility and method of improving the solubility of an amide-containing compound
CA2464358C (en) * 2001-10-19 2011-05-24 Toyama Chemical Co., Ltd. Alkyl ether derivatives or their salts
NZ537090A (en) * 2002-06-14 2006-02-24 Toyama Chemical Co Ltd Medicinal compositions improving brain function and method for improving brain function
AU2007244409B2 (en) * 2006-04-26 2011-12-01 Toyama Chemical Co., Ltd. Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof
ZA200900743B (en) * 2006-08-04 2010-05-26 Toyama Chemical Co Ltd Protein kinase C activity enhancer containing alkyl ether derivative or salt thereof

Also Published As

Publication number Publication date
IL209443A0 (en) 2011-01-31
PT2287160E (pt) 2014-06-24
CA2725307C (en) 2015-12-22
US20110077413A1 (en) 2011-03-31
SI2287160T1 (sl) 2014-09-30
JP5552424B2 (ja) 2014-07-16
AU2009252368B2 (en) 2013-10-03
CN102046620B (zh) 2014-04-09
DK2287160T3 (da) 2014-06-10
HRP20140495T1 (hr) 2014-07-04
BRPI0912266B8 (pt) 2021-05-25
CY1115355T1 (el) 2017-01-04
NZ589448A (en) 2011-09-30
BRPI0912266B1 (pt) 2019-07-09
KR20110010741A (ko) 2011-02-07
MX2010012787A (es) 2011-02-24
ES2465005T3 (es) 2014-06-04
ZA201008354B (en) 2012-02-29
IL209443A (en) 2014-02-27
AU2009252368A1 (en) 2009-12-03
EP2287160B1 (en) 2014-05-07
US8026232B2 (en) 2011-09-27
KR101615114B1 (ko) 2016-04-25
EP2287160A4 (en) 2012-01-04
JPWO2009145171A1 (ja) 2011-10-13
WO2009145171A1 (ja) 2009-12-03
CA2725307A1 (en) 2009-12-03
CN102046620A (zh) 2011-05-04
PL2287160T3 (pl) 2014-09-30
EP2287160A1 (en) 2011-02-23

Similar Documents

Publication Publication Date Title
BRPI0906962A2 (pt) Composto, e, composição farmacêutica
BRPI0906556A2 (pt) Composto, e, composição farmacêutica
SMT201600259B (it) Composizioni farmaceutiche antibatteriche
BRPI1012892A2 (pt) composto, e, composição farmacêutica.
BRPI0917681A2 (pt) Composto, e, composição farmacêutica
BRPI0715712A2 (pt) Composição farmacêutica
BRPI1007379A2 (pt) composições e métodos para o tratamento ou a prevenção de infecções orais por e. coli
BRPI0719393A2 (pt) Composição farmacêutica
BR112014014769A2 (pt) Composto, composição farmacêutica, e, uso de um composto ou sal.
BRPI0909738A2 (pt) composições farmacêuticas aquosas contendo complexos de boratopoliol
DK2108260T3 (da) Sammensætning med biocid aktivitet til vandige præparater
BRPI0905369A2 (pt) Composição farmacêutica, composição e kit compartimentado
BRPI0720234A2 (pt) Composição farmacêutica
BRPI0716445A2 (pt) composiÇço farmacÊutica
DK2285413T3 (da) Farmaceutisk sammensætning
BRPI0921313A2 (pt) composição farmaucêutica
PT2193795E (pt) Composição farmacêutica aquosa contendo latanoprost
BRPI1010300A2 (pt) processos para a preparação de um composto, para perparar dronedarone, ou um sal do mesmo, e para preparar uma formulação farmacêutica.
BRPI0922286A2 (pt) composto de quinolona e composição farmacêutica.
BRPI0812359A2 (pt) Derivado de tetra-hidroisoquinolin-1-ona ou sal do mesmo
BRPI0912118A2 (pt) composto, composição farmacêutica, e, intermediário sintético
BRPI0812234A2 (pt) Composto de quinolona e composição farmacêutica.
BRPI0914182A2 (pt) composto, e, composição farmacêutica
BRPI0912171A2 (pt) composição farmacêutica
BRPI0806938A2 (pt) Composição farmacêutica contedo um derivado de camptotecina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/07/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/07/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/05/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2829 DE 25-03-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.